Incidence and Prevalence of Polymyalgia Rheumatic and Giant Cell Arteritis: A 15-Year Study in a Health Care Management Organization - ACR Meeting Abstracts

ABSTRACT NUMBER: 1190
Incidence and Prevalence of Polymyalgia Rheumatic and
Giant Cell Arteritis: A 15-Year Study in a Health Care
Management Organization
Jose Maximiliano Martinez P1, Florencia Beatriz Mollerach2, Facundo Vergara2, Ignacio Javier
Gandino2, Marina Scolnik3, Luis J. Catoggio4, Javier Rosa2 and Enrique R. Soriano2, 1Rheumatology,
Internal Medicine Service, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos
Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos
Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires,
Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires,
Argentina, 3Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de
Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio,
Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos
Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio,
Argentina., Buenos Aires, Argentina
Meeting: 2016 ACR/ARHP Annual Meeting
Date of !rst publication: September 28, 2016
Keywords: Epidemiologic methods, giant cell arteritis and polymyalgia rheumatica
SESSION INFORMATION
Date: Monday, November 14, 2016
Session Type: ACR Poster Session B
Session Title: Epidemiology and Public
Health - Poster II
Session Time: 9:00AM-11:00AM
Background/Purpose: There is scarce information on the epidemiology of polymyalgia rheumatic
(PMR) and giant cell arteritis (GCA) in Latin America. To estimate incidence and prevalence rates of
PMR and GCA in a large university hospital–based health management organization in South
America.
Methods: Global, age-speci!c, and sex-speci!c incidence and prevalence rates were calculated for
members of a Medical Care Program (HIMCP), age ≥ 50 years. Incidence study followed members
with continuous a"liation ≥ 6 months from January 2000 to December 2015 until he/she voluntarily
left the HIMCP, PMR or GCA were diagnosed, death, or study !nalization. Cases from the
Rheumatology Section database, electronic medical records, laboratory database, temporal artery
biopsy and pharmacy database were !ltered with the 2012 EULAR/ACR criteria for PMR or the ACR
1990 criteria for GCA. Prevalence was calculated on January 1, 2015.
Results: : In the study period 176,558 persons contributed a total of 1,046,620 person-years, of who
825 developed PMR for an overall incidence rate (cases per 100,000 person-years) of 78.8 (95% CI
73.4–84.2), 90.1 (95% CI 82.9–97.2) for women, and 58.9 (95% CI 51.1–66.6) for men. Ninety persons
developed GCA for an overall incidence rate of 8.6 (95% CI 6.8–10.4), 11.1 (95% CI 8.5–10.6) for
women, and 4.2 (2.2–6.3) for men. On January 1, 2015, 899 prevalent PMR cases and 100 prevalent
ACG cases were identi!ed from a denominator population of 80335 HIMCP members. Prevalence
rates of PMR (percentage of cases in the sample population) were 11.2 per 1000 (95% CI 10.4–11.9)
overall, 12.7 (95% CI 11.8–13.7) for women, and 8.2 (95% CI 7.2–9.3) for men, and prevalence rates of
GCA were 1.2 per 1000 (95% CI 1–1.4) overall, 1.5 (95% CI 1.2–1.9) for women, and 6.3 (95% CI 3.4–9.3)
for men. Patient’s characteristics and incidence and prevalence rates per gender and di#erent age
groups are shown in table 1 and !gures 1 and 2 respectively.
Conclusion: This study’s incidence and prevalence rates are in the upper range of the rates found
around the world. Our peak incidence age for PMR was in the eighth decade for both sexes and for
GCA was in the seventh decades for both sexes.
Disclosure: J. M. Martinez P, None; F. B. Mollerach, None; F. Vergara, None; I. J. Gandino, None;
M. Scolnik, None; L. J. Catoggio, None; J. Rosa, None; E. R. Soriano, Abbvie, 2,P!zer Inc, 3,UCB,
2,Janssen Pharmaceutica Product, L.P., 2,Roche Pharmaceuticals, 2,Bristol-Myers Squibb, 2,Abbvie,
5,P!zer Inc, 5,UCB, 5,Janssen Pharmaceutica Product, L.P., 5,Roche Pharmaceuticals, 5,Novartis
Pharmaceutical Corporation, 5,Bristol-Myers Squibb, 5.
To cite this abstract in AMA style:
Martinez P JM, Mollerach FB, Vergara F, Gandino IJ, Scolnik M, Catoggio LJ, Rosa J, Soriano ER.
Incidence and Prevalence of Polymyalgia Rheumatic and Giant Cell Arteritis: A 15-Year Study in a
Health Care Management Organization [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
https://acrabstracts.org/abstract/incidence-and-prevalence-of-polymyalgia-rheumatic-and-giantcell-arteritis-a-15-year-study-in-a-health-care-management-organization/. Accessed November
17, 2020.
ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-prevalence-of-polymyalgiarheumatic-and-giant-cell-arteritis-a-15-year-study-in-a-health-care-management-organization/